SAN DIEGO, Dec. 04, 2012 \/PRNewswire\/ --OncoSec Medical Inc. (ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers, announced it will be presenting at the DNA Vaccines 2012 Conference at the Loews Coronado Bay Resort in San Diego, California. OncoSec is a Silver Sponsor of the conference. <\/p>\n
(Logo: http:\/\/photos.prnewswire.com\/prnh\/20110314\/MM64943LOGO<\/a>) <\/p>\n The Company will conduct two presentations within the Cancer Immune Therapy Track on Thursday, December 6: <\/p>\n From 11:30 AM-12:00 PM PT, Richard Heller, Ph.D., director of the Frank Reidy Research Center for Bioelectrics at Old Dominion University, will speak on \"Gene Electrotransfer for the Enhanced Delivery of Immunomodulating Agents.\" In this presentation, Dr. Heller will present data on electroporation and delivery of plasmids for cancer immunotherapy, a technology used in OncoSec's ImmunoPulse therapy. <\/p>\n From 12:00 PM-12:30 PM PT, Adil Daud, M.D., clinical professor of medicine and dermatology and director of the melanoma program at the University of California, San Francisco, will speak on \"Clinical Studies of Melanoma Therapy.\" In this presentation, Dr. Daud will be reviewing previously presented interim data from OncoSec's ongoing Phase II trial for metastatic melanoma for which he is principal investigator. <\/p>\n The DNA Vaccines Conference brings in an array of researchers from all corners of the world to present new cutting-edge discoveries in DNA vaccines that have never before been presented or published at any other meeting. For more information about the conference, please visit: http:\/\/www.bioconferences.com\/conferences\/dna\/index.aspx<\/a> <\/p>\n About OncoSec Medical Inc. <\/p>\n OncoSec Medical Inc. isa biopharmaceutical companydeveloping its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumor cancers.ImmunoPulse and NeoPulse therapiesaddress an unmet medical needandrepresenta potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives. OncoSec Medical's core technology is based upon its proprietaryuse of anelectroporation platform todramatically enhancethedelivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent(NeoPulse). Treatment ofvarious solid cancersusing these powerfuland targetedanti-cancer agentshas demonstratedselective destruction of cancerous cellswhile sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for ImmunoPulse targeting lethal skin cancers. More information is available athttp:\/\/www.oncosec.com\/. <\/p>\n This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such \"forward looking statements.\" Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. <\/p>\n <\/p>\n Here is the original post: SAN DIEGO, Dec. 04, 2012 \/PRNewswire\/ --OncoSec Medical Inc. Continue reading
\nOncoSec Medical to Present Data at DNA Vaccines 2012 Conference<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"